MUC1* Ligand Stem Cell Culture Media for Naïve State Maintenance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current stem cell growth media, particularly for human embryonic and induced pluripotent stem cells, rely on undefined components and high levels of basic fibroblast growth factor (bFGF), which stabilizes cells in a 'primed' state, limiting their ability to differentiate into various cell types required for therapeutic applications, and poses regulatory challenges due to irreproducibility and potential unforeseen effects from high growth factor levels.
Innovation Solution
A cell culture media using a MUC1* activating ligand, such as NME family proteins like NME1, which can induce stem cells to revert to a less mature, pluripotent state without bFGF and TGF-beta, allowing for serum-free growth and maintenance of naïve stem cells, and includes inhibitors of rho-associated kinase and guanine exchange factors to promote pluripotency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If basic fibroblast growth factor (bFGF) is used to maintain stem cell growth, then stem cell proliferation is supported, but cells are stabilized in a 'primed' state which limits their ability to differentiate into various cell types
Solution Approach 1:
The patent removes bFGF and TGF-beta from the culture media, extracting the problematic growth factors that stabilize cells in a primed state. This extraction allows cells to revert to a naive pluripotent state while maintaining proliferation through alternative mechanisms involving MUC1* activating ligands and rho-associated kinase inhibitors.
Solution Approach 2:
The patent changes the chemical parameters of the culture media by eliminating bFGF and TGF-beta, and instead using defined components including MUC1* activating ligands (such as NME family proteins) and rho-associated kinase inhibitors. This parameter change enables cells to transition from a primed to a naive state while maintaining growth capability.
2Productivity
If complex mixtures of undefined components are used to culture stem cells, then cell growth is maintained, but regulatory approval becomes difficult due to irreproducibility and safety concerns
Solution Approach 1:
The patent extracts and eliminates undefined components from the culture system, including removal of feeder cells and replacement with defined extracellular matrix coatings. The media composition is fully defined without serum or undefined supplements, enabling reproducible manufacturing under GMP conditions.
Solution Approach 2:
The patent employs a self-sufficient culture system where stem cells are maintained on defined extracellular matrix coatings without requiring feeder cells or conditioned media. The system is self-contained with all necessary growth factors and signaling molecules provided in defined concentrations in the culture media itself.
3Productivity
If high levels of bFGF are used to maintain stem cells, then cell proliferation is enhanced, but unforeseen effects may occur and physiological relevance is compromised
Solution Approach 1:
The patent removes high concentrations of bFGF from the culture system, eliminating the source of unforeseen effects and non-physiological conditions. Proliferation is maintained through alternative pathways involving MUC1* activation and rho-associated kinase inhibition, which operate at physiological concentrations.
Solution Approach 2:
The patent changes the growth factor concentration parameters from high levels of bFGF to physiological levels of defined growth factors and signaling molecules. This parameter change maintains cell proliferation while ensuring physiological relevance and eliminating harmful effects associated with supraphysiological growth factor concentrations.
Data Source
AI summary
The present application discloses a cell culture media for growth, maintenance and induction of reversion to a less mature state of a cell comprising a MUC1* activating ligand.